Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2024 · 10-Q
Revenue—
Net Income-$684.71K-$684.71KN/M vs Q1 2023 EPS Diluted$0.00$0.00— vs Q1 2023 Operating Income-$774,817N/M Operating Cash Flow-$1,158,091N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 13, 2024 · 43 d after period end